INTECH Investment Management’s Travere Therapeutics TVTX Stock Holding History

INTECH Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	20,038 -2,503	-11%	-$111K	0.01%	967
2026 Q1	$670K	Sell	22,541 -17,859	-44%	-$534K	0.01%	1197
2025 Q4	$1.54M	Buy	40,400 +12,858	+47%	+$418K	0.01%	881
2025 Q3	$658K	Sell	27,542 -11,455	-29%	-$215K	0.01%	1423
2025 Q2	$577K	Sell	38,997 -14,197	-27%	-$235K	0.01%	1523
2025 Q1	$953K	Buy	53,194 +20,718	+64%	+$420K	0.01%	1226
2024 Q4	$566K	Buy	32,476 +12,250	+61%	+$217K	0.01%	1489
2024 Q3	$283K	Buy	+20,226	New	+$211K	﹤0.01%	1546

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

INTECH Investment Management's TVTX Position: Q2 2026 in Review

INTECH Investment Management reduced its Travere Therapeutics (TVTX) stake by 11% in Q2 2026, selling an estimated $111K and leaving 20,038 shares worth $1.14M. The position accounts for 0.01% of the portfolio, ranked #967.

INTECH Investment Management first reported a position in TVTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.54M in Q4 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

INTECH Investment Management held 20,038 shares of Travere Therapeutics worth $1.14M as of Q2 2026.
INTECH Investment Management sold 2,503 Travere Therapeutics shares in Q2 2026, an estimated $111K.
Travere Therapeutics made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #967 holding.
INTECH Investment Management first reported a position in Travere Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Travere Therapeutics position peaked at $1.54M in Q4 2025.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.